Trellus Health Issues New Shares on Loan Note Conversion, Lifts Voting Share Count to 322.3m

Trellus Health PLC ( (GB:TRLS) ) has shared an update.

Trellus Health has issued 48,692,603 new ordinary shares following the conversion of £50,000 of principal under the second tranche of its secured convertible loan notes, expanding its equity base. The new shares are expected to be admitted to trading on AIM around 13 April 2026, taking the company’s total shares in issue to 322,330,221 and resetting the denominator used by investors for disclosure of voting interests under FCA transparency rules.

The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.

Spark’s Take on TRLS Stock

According to Spark, TipRanks’ AI Analyst, TRLS is a Neutral.

The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.

To see Spark’s full report on TRLS stock, click here.

More about Trellus Health PLC

Trellus Health plc is a healthcare company that delivers Trellus Elevate, a digital, whole-person condition management platform that integrates data analytics, resilience-based methodology, and personalised coaching to support patients with complex chronic diseases. The group initially targets costly gastrointestinal conditions with high mental health burden, such as inflammatory bowel disease, and also partners with pharmaceutical companies from clinical trials through commercialisation.

Average Trading Volume: 7,980,747

Technical Sentiment Signal: Sell

Current Market Cap: £478.9K

For a thorough assessment of TRLS stock, go to TipRanks’ Stock Analysis page.